Now FDA Approved

SARCLISA is a prescription medicine used in combination with pomalidomide and dexamethasone to treat adults who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma.

Proteasome inhibitors include medicines such as Kyprolis® (carfilzomib), Ninlaro® (ixazomib), and Velcade® (bortezomib).

Get the Latest Updates

Talk With Your Doctor

Press Release

Prescribing Information

CareASSIST by Sanofi Genzyme helps eligible patients with access and support for SARCLISA. Explore the services and resources available to help you get started and stay on track with SARCLISA.

If you have commercial insurance, you may be eligible for the CareASSIST Copay Program. If you qualify, your out-of-pocket costs may be as little as $0. Learn more.

Access and
Reimbursement

CareASSIST can help determine insurance coverage and options.

Financial Assistance

CareASSIST offers programs and services that can help eligible patients with the cost of treatment.

Resource Support

CareASSIST can identify other resources and support that may be available.

To learn more about CareASSIST for SARCLISA, call 1-833-WE+CARE
(1-833-930-2273), Mon – Fri, 9 AM – 8 PM ET, or visit SanofiCareAssist.com/sarclisa.

Learn More

Get the latest updates about SARCLISA

There is much more information about SARCLISA coming soon. Register below to get the latest about SARCLISA as soon as it becomes available, including updates to this website and helpful resources.

All fields are required unless otherwise noted.

First Name

Last Name

Address

Address 2 (optional)

ZIP Code

City

State

Email Address

Please select the option that best applies. I am a patient who has been prescribed SARCLISA. I am a patient who is interested in treatment with SARCLISA. I care for a patient who has been prescribed SARCLISA. I care for a patient who is interested in treatment with SARCLISA.

I am 18 years of age or older.

By checking this box, I agree that Sanofi Genzyme, its affiliates, and agents (such as third-party business partners) can: send me information about multiple myeloma and Sanofi Genzyme products, promotions, services, and research studies; ask my opinion about such information and topics, including market research and disease-related surveys; and share the information I provide with one another to perform these activities, and to de-identify it for use in performing research, education, business analytics, marketing studies, and other commercial purposes. I understand that my information will not be sold to any third party. I understand that I may opt out of continued receipt of such communications at any time by calling 1-855-676-6326.

Get the latest updates about SARCLISA

YOU HAVE CHOSEN TO LEAVE THE CONTROLOFMYDIABETES.COM WEBSITE

You are about to leave sanofi site for U.S.

You are about to move to an Unbranded site

Our commitment to patients during COVID-19